ARTICLE | Clinical News
GVAX vaccine for prostate cancer: Development restarted
May 17, 2010 7:00 AM UTC
BioSante restarted development of GVAX immunotherapy to treat prostate cancer and expects to begin a Phase II trial in 4Q10. The company said it is taking steps to lift the clinical hold on the progra...